Related by context. All words. (Click for frequent words.) 72 CBLC# 71 alvespimycin 71 ONCONASE R 70 IRX 2 70 HGS ETR1 70 CTAP# Capsules 70 PXD# 70 drug GAP #B# 70 oral prodrug 69 Archexin 69 HGS ETR2 69 Locteron ® 69 mitogen activated ERK kinase 69 anticancer compound 68 TRO# 68 AEG# 68 Azedra 68 R#/MEM # 68 Curaxin CBLC# 68 CYT# potent vascular disrupting 68 IMA# 68 FOLOTYN ® 68 compound INCB# 68 ZK EPO 68 Panzem R 68 TOCOSOL Camptothecin 67 vascular disrupting agent 67 Tyrima 67 phase IIb clinical 67 HuMax EGFr 67 virus HCV protease inhibitor 67 registrational trial 67 PI3K/Akt pathway inhibitor 67 enzastaurin 67 CR# vcMMAE 67 candidate deforolimus 67 Exherin TM 67 refractory gout 67 Phase IIb clinical trials 67 unique alkylating agent 67 CD# CEA 67 Celacade TM technology 67 Tarvacin TM 67 Phase Ib clinical trials 67 anticoagulant reversing agent 67 velafermin 67 LymphoStat B belimumab 67 Genasense ® oblimersen 66 Symadex 66 preclinically 66 2 methoxyestradiol 66 investigational HCV polymerase 66 apricitabine ATC 66 PHX# 66 phase IIa clinical 66 Phase 2a trial 66 oral picoplatin 66 OncoVEX GM CSF 66 mapatumumab 66 ganetespib 66 ApoB SNALP 66 candidate CRLX# 66 lomitapide 66 Solazed TM 66 vidofludimus 66 sodium Injection 66 HGS# 66 forodesine 66 PSN# [002] 66 GED aPC 66 Fx #A 66 investigational humanized monoclonal antibody 66 kidney urologic 66 PRT# 66 LymphoStat B TM 66 DXL# 66 Atiprimod 66 CA4P 66 ImmunoVEX HSV2 66 Sym# 66 radiation sensitizer 66 trastuzumab DM1 T DM1 66 axitinib 66 candidate epratuzumab 66 elotuzumab 66 Bayer HealthCare Onyx Pharmaceuticals 66 pharmacokinetic PK study 66 Virulizin ® 66 Cannabinor 65 PEG SN# 65 RLY# 65 PDX pralatrexate 65 NP2 Enkephalin 65 liposomal formulation 65 Phase #b/#a clinical 65 evaluating tivozanib 65 MCSP respectively 65 MEK inhibitor 65 DPX Survivac 65 cMET 65 Panzem 65 Deforolimus 65 mGluR5 negative 65 FOLFOX6 chemotherapy regimen 65 Personalized Immunotherapy 65 TACI Ig 65 candidate XP# 65 tiapamil 65 ENMD # 65 Zalypsis 65 CRLX# 65 MEK inhibitors 65 huC# DM4 65 Azedra TM 65 candidate voreloxin 65 Panzem R NCD 65 investigational pan BCR 65 PROVENGE sipuleucel T 65 JAK inhibitor 65 PANVAC VF 65 Tarvacin Anti Cancer 65 investigational monoclonal antibody 65 Proxinium TM 65 next generation URAT1 65 Phase Ib II 65 rNAPc2 65 PLK1 SNALP 65 INCB# [001] 65 metaglidasen 65 hypoxia selective 65 MAGE A3 ASCI 65 riociguat 65 ADI PEG 65 AKT inhibitor 65 Xanafide 65 drug ISA# 65 ospemifene 65 personalized immunotherapy 65 HIV RDEA# 65 Glufosfamide 64 oral ridaforolimus 64 acetonide FA 64 ThermoDox ® clinical 64 JAK1 64 ELACYT 64 elacytarabine 64 ostarine 64 PDE4 inhibitor 64 Phase IIb trials 64 Onconase 64 mGluR2 NAM 64 cediranib 64 XL# anticancer compounds 64 cancer immunotherapies 64 rALLy clinical trial 64 Phase 1b trial 64 Neuradiab 64 Hepatocellular Carcinoma HCC 64 Phase Ib 64 TBC# 64 OvaRex R 64 Cintredekin Besudotox 64 Phase Ib study 64 tolerability pharmacokinetics 64 Phase 1b clinical trials 64 histone deacetylase inhibitor 64 hypoxia activated prodrug 64 candidates bavituximab 64 Phase 2a clinical trials 64 obatoclax 64 preclinical efficacy 64 TLK# 64 small molecule defensin 64 ALS #-# 64 davunetide intranasal AL 64 candidate Zenvia 64 multicenter Phase II 64 indibulin 64 ThermoDox R 64 velafermin belinostat 64 selective androgen receptor modulator 64 MGCD# [001] 64 EOquin TM 64 Phase 2a clinical 64 pediatric malignancies 64 pertuzumab 64 tramiprosate Alzhemed TM 64 ZYBRESTAT fosbretabulin 64 epigenetic therapies 64 CB2 selective receptor agonist 64 PNP inhibitor 64 trial evaluating PRX# 64 deforolimus 64 compound PMX # 64 tezampanel 64 mertansine 64 CCR9 antagonist 64 IL# PE#QQR 64 Tezampanel 64 eniluracil 64 generation Hsp# inhibitor 64 sorafenib tablets 64 sulodexide 64 anti amnesic 64 HGS ETR1 mapatumumab 64 PSMA ADC 64 CRMD# 64 SUCCEED trial 64 RDEA# 64 Oracea TM 64 Trofex TM 64 eprotirome 64 Phase IIb clinical 64 #/#/# Cytokinetics Incorporated 63 ALN PCS 63 Aplidin 63 tanespimycin 63 pralatrexate injection folate analogue 63 OMP #M# 63 Tasimelteon 63 TPI ASM8 63 RGB # 63 polysaccharide polymer 63 Nanobody ® 63 Angiocept 63 ASONEP 63 tesmilifene 63 Phase Ib clinical 63 Genasense R oblimersen 63 teriflunomide 63 including eniluracil ADH 63 Phase IIb III 63 Ophena 63 otelixizumab 63 adecatumumab 63 entinostat 63 rifalazil 63 BENLYSTA ™ 63 Hsp# inhibitor 63 RSD# oral 63 sapacitabine 63 Xcytrin R 63 isoform selective 63 lucinactant 63 ALV# 63 VEGFR2 inhibitor 63 dextofisopam 63 vosaroxin 63 GALNS 63 Hematide ™ 63 torezolid phosphate 63 erlotinib Tarceva ® 63 molecular imaging radiopharmaceutical 63 targeted radiotherapeutic 63 GLYX 63 BZL# 63 PS# DARA 63 immunological diseases 63 Alocrest 63 Bezielle 63 farletuzumab 63 MyVax R 63 therapeutic monoclonal antibody 63 fosbretabulin 63 Carfilzomib 63 ALN VSP 63 Exelixis compounds 63 sapacitabine CYC# 63 vascular disrupting agents 63 NOX E# 63 Ophena TM 63 Elagolix 63 tubulin inhibitor 63 BRAF inhibitor 63 allosteric modulator 63 fibrotic disease 63 EMPOWER ™ 63 preclinical studies Vion 63 selective kinase inhibitor 63 CINQUIL 63 Cleviprex TM clevidipine 63 BrachySil 63 anticancer agent 63 cannabinor 63 Celacade TM 63 MYDICAR ® 63 dose escalation Phase 63 generation URAT1 inhibitor 63 Phase #b/#a 63 OTCBB PYTO 63 zanolimumab 63 systemically administered 63 neratinib 63 CORT # 63 KNS # 63 HCV protease 63 OvaRex ® MAb 63 phase Ib clinical 63 histamine dihydrochloride 63 Perflubutane Polymer Microspheres 63 GATTEX ® 63 oral JAK#/JAK# inhibitor 63 Imprime PGG ® 63 HuLuc# 63 CCX# 63 CEQ# 63 Myocet 63 oral deforolimus 63 Telatinib 63 receptor tyrosine kinase inhibitor 63 Rigel R# 63 candidate brentuximab vedotin 63 compound perifosine 63 Phase 1b 63 Metastatic Melanoma 63 oral proteasome inhibitor 63 intravenous ghrelin agonist 63 REOLYSIN ® 63 Bioral Amphotericin B 63 tivozanib 63 MEND CABG 63 pomalidomide 63 GAP #B# 63 Hsp# Inhibitor 63 oral isotype selective HDAC 63 Ceflatonin R 63 antisense inhibitors 63 IIa trial 63 EndoTAG TM -1 63 Amplimexon 63 Perifosine 63 talactoferrin 62 depsipeptide 62 TELCYTA 62 GLP toxicology studies 62 Stedivaze 62 ThGRF 62 HER2 positive metastatic breast 62 registrational 62 TELINTRA 62 LibiGel ® 62 Traficet EN 62 theranostic 62 GRN# 62 PRTX 62 MET amplification 62 selective angiogenic kinase inhibitor 62 personalized cellular immunotherapy 62 cilengitide 62 ongoing Phase 1b 62 NEUVENGE 62 RNAi therapeutic targeting 62 ATL# [002] 62 OHR/AVR# 62 Safinamide 62 Capesaris 62 product Hextend ® 62 lapatinib Tykerb 62 Omacetaxine 62 TTF Therapy 62 SinuNase TM 62 Zybrestat 62 CoFactor 62 Mipomersen 62 Nanobody R 62 docetaxel Taxotere R 62 CTA# Injection 62 anti fibrotic 62 leading oral taxane 62 Aurora kinase 62 Seliciclib 62 DAVANAT 62 Aganocide 62 sodium thiosulfate STS 62 ozarelix 62 TRV# [001] 62 antibody MAb 62 Insegia 62 Annamycin 62 Vidofludimus 62 APOPTONE 62 YONDELIS 62 Quinamed 62 trastuzumab emtansine T DM1 62 HQK 62 Afatinib 62 ancrod 62 acyclovir Lauriad R 62 product platforms AZX# 62 Protexia ® 62 MBP# [001] 62 Nexavar sorafenib 62 IND submission 62 XmAb# 62 HCV protease inhibitor 62 Friedreich Ataxia FRDA 62 lorvotuzumab mertansine 62 Tanespimycin 62 IMP# 62 highly selective inhibitor 62 Tectin TM 62 TRIOLEX 62 Chemokine Therapeutics 62 Neo Kidney Augment 62 nicotinic alpha 7 62 LUX Lung 62 recurrent metastatic ovarian cancer 62 candidate EFAPROXYN TM 62 pharmacological chaperone compounds 62 Adnectin 62 Prodarsan 62 Spiegelmer ® 62 Inc. AMEX YMI 62 oral ghrelin agonist 62 phase IIb trial 62 AQ4N 62 Phase III Pivotal 62 MGN# 62 Hsp# inhibition 62 Oral NKTR 62 BiovaxID TM 62 Phase 2b clinical 62 optimal dosing regimens 62 ZADAXIN ® 62 ARRY # 62 HCV NS5B polymerase 62 recurrent glioblastoma 62 midstage trials 62 systemic anaplastic large 62 EXPLORE Xa 62 ulimorelin 62 pan HDAC inhibitor 62 Tesetaxel 62 Inc. OTCBB IRBS 62 dirucotide 62 demonstrated antitumor activity 62 pralatrexate 62 delivers fluocinolone acetonide FA 62 varespladib 62 compound AEOL # 62 CDK inhibitor 62 nonclinical studies 62 JAK2 inhibitor 62 CYT# vascular disrupting 62 bevacizumab Avastin ® 62 Cloretazine ® 62 RAV# 62 novel VDA molecule 62 Intarcia 62 GSK# [002] 62 Phase #/#a trial 62 Cylene 62 OMAPRO 62 GRN#L 62 RenaZorb TM 62 glufosfamide 62 Triolex 62 ATL/TV# 62 Zerenex 62 QTinno TM 62 talabostat 62 Microplasmin 62 confirmatory Phase III 62 orally administered inhibitor 62 evaluating picoplatin 62 Diamyd R 62 ruxolitinib 62 phase IIb 62 ocular formulation 62 Phase III confirmatory 62 Combination REOLYSIN R 62 IMPDH inhibitor 62 castrate resistant prostate cancer 62 INSPIRE Trial Phase III 62 sunitinib malate 62 OncoVEX 62 Lisofylline LSF 62 biased ligand 62 pipeline GlycoPEG GCSF 62 Sapacitabine 61 bazedoxifene conjugated estrogens 61 oral salmon calcitonin 61 BLA filing 61 tremelimumab 61 teplizumab 61 OvaRex 61 ISIS # 61 lead Aganocide compound 61 Troxatyl 61 allosteric modulator NAM 61 MKC# MT 61 Injectable Suspension 61 ALN TTR 61 non nucleoside inhibitor 61 TNFerade ™ 61 PS# [001] 61 IMiDs 61 Aflibercept 61 Guanilib 61 Ozarelix 61 Serdaxin ® 61 metastatic colorectal 61 Prodarsan ® 61 teduglutide 61 signal transduction inhibitor 61 radezolid 61 elesclomol 61 Phase 2a 61 THR beta agonist 61 MGd 61 P2V TM 61 HDL Mimetic Peptide 61 5 HT6 receptor 61 Phase IIa trials 61 therapeutic monoclonal antibodies 61 gastro intestinal inflammation 61 renin inhibitors 61 ON #.Na 61 Zoraxel 61 myeloproliferative disorders 61 L BLP# 61 OXi# 61 candidate AQ4N 61 investigational hepatitis C 61 novel antifolate currently 61 CYT# novel 61 PTP 1B 61 candidate TNFerade biologic 61 P#X# antagonist 61 bavituximab monotherapy trial 61 Vicinium TM 61 blood serum biomarkers 61 REG1 61 Inc. Nasdaq RDEA 61 investigational therapies 61 orally bioavailable 61 myelofibrosis polycythemia vera 61 Alzhemed TM 61 alagebrium 61 TG# [003] 61 Aurexis 61 EVIZON TM squalamine lactate 61 leukotriene pathway 61 NASDAQ SNTA 61 midstage clinical 61 Apaziquone 61 metastatic castration resistant 61 small molecule activator 61 cariprazine 61 LungExpress Dx TM 61 AVN# [001] 61 nucleotide analog 61 Valortim 61 brivaracetam 61 phase IIa 61 Cloretazine R VNP#M 61 Zemiva TM 61 TOCOSOL Paclitaxel 61 IAP inhibitor 61 Blinatumomab 61 sarcoma melanoma 61 Lenocta TM 61 IMC A# 61 MEND CABG II 61 treat refractory angina 61 Tavocept 61 bardoxolone 61 GMX# 61 oncolytic virus therapies 61 trastuzumab Herceptin R 61 Prodarsan R 61 ARIKACE ™ 61 Ceflatonin ® 61 Fibrin MB 61 voreloxin 61 oxidative stress inducer 61 LibiGel Phase III 61 ANAVEX #-# [003] 61 Durata 61 antibody MT# 61 Phase IIB 61 trodusquemine 61 polymerase inhibitors 61 Sphingomab TM 61 MDV# 61 ProSavin 61 LHRH antagonists 61 Genasense oblimersen sodium Injection 61 inhibit metastasis 61 AAG geldanamycin analog 61 MOR# 61 generation proteasome inhibitor 61 NS5B polymerase 61 targets Galectin receptors 61 Cloretazine 61 NTx TM -# 61 PRIMO CABG 61 assessing T DM1 61 BrachySil TM 61 EDEMA3 trial 61 APEX PD 61 Celator 61 ABL inhibitor 61 PRE SURGE 61 XL# XL# 61 vinca alkaloid 61 Maximum Tolerated Dose MTD 61 PrevOnco ™ 61 Nanobody 61 sorafenib Nexavar ® 61 R roscovitine 61 Amrubicin 61 favorable pharmacokinetic profile 61 evaluating satraplatin 61 Diamyd ® 61 JAK inhibitors 61 pharmacological chaperone 61 Epothilone D 61 faropenem medoxomil 61 RAS MAPK pathway 61 Ceflatonin 61 EFAPROXYN 61 Darinaparsin 61 belinostat 61 Elotuzumab 61 aerosolized KL4 surfactant 61 compound COTI 61 candidate MyVax 61 XL# SAR# 61 Phase 2b Trial 61 Icatibant 61 refractory chronic lymphocytic 61 NIC5 61 Smac mimetics 61 Phenserine 61 glucokinase activator 61 PEGPH# 61 GRNCM1 61 Telik logo TELINTRA 61 multi kinase inhibitor 61 cystinosis patients 61 INCB# [003] 61 Squalamine 61 tezampanel NGX# 61 huN# DM1 61 SAR# [002] 61 adecatumumab MT# 61 GSK # 61 urocortin 2 61 pharmacogenetic test 61 iSONEP 61 CK # novel 61 phase 2a 61 vivo glucose 61 NEUMUNE 61 afatinib 61 ToGA 61 Cetrorelix 61 MOZOBIL 61 candidate Liposomal Grb 61 Plicera 61 CYC# 61 Pervasis 61 GATTEX ™ 61 SCH # 61 phase IIb study 61 Selective Electrochemical Tumor Ablation 61 Cand5 61 LE DT 61 Chrysalin 61 Ocrelizumab 61 olaparib 61 INT# [002] 61 ELND-#/AZD-# 61 cardio renal 61 autologous cellular immunotherapy 61 ongoing Phase IIIb 61 relapsed multiple myeloma 61 bucindolol hydrochloride 61 Novolimus 61 Anturol ® 61 modified glutathione analog 61 Initiates Phase II 61 oral taxane 61 HCV protease inhibitors 60 Entereg R 60 TKB# 60 CINTREDEKIN BESUDOTOX 60 orBec R oral beclomethasone 60 Allovectin 7 60 Phase 2b study 60 LE SN# 60 endothelin antagonist 60 ONCONASE 60 AMR# 60 oral gallium 60 nucleoside tide 60 PKC# 60 Prostate AdenoCarcinoma Treatment 60 kinase inhibition 60 IMC #B 60 Immunotherapeutic 60 compound AEZS 60 generation purine nucleoside 60 SNT MC# 60 ICA # 60 BiTE antibody 60 #ME# 60 intravenous methylnaltrexone 60 ACAPODENE TM 60 candidate ridaforolimus 60 CLORETAZINE TM VNP#M 60 pseudobulbar affect PBA 60 Phase #b/#a trial 60 ORE# 60 PROSTVAC TM 60 ARIKACE 60 European Sepsis Trial 60 mTOR inhibition 60 AKIP ™ 60 TRAIL receptor antibodies 60 DCVax R 60 Trophos 60 maximally tolerated dose 60 Aviptadil 60 ANAVEX #-# [001] 60 Anturol TM 60 Gleevec resistant 60 palifosfamide 60 telomerase therapeutic 60 Genz # 60 BAY #-# 60 Trofex 60 Imprime PGG 60 Valortim ® 60 Aeolus Pharmaceuticals 60 solid tumors ZYBRESTAT 60 product Fentanyl TAIFUN 60 small molecule activators 60 oxybutynin ATD TM 60 GLPG# 60 TKM PLK1 60 relapsed MM 60 seliciclib CYC# 60 IIa clinical 60 selective immunoproteasome inhibitor 60 reversible inhibitor 60 crizotinib PF # 60 ATL# [001] 60 PLX cells 60 immunotherapeutics 60 Pimavanserin 60 Ketotransdel ® 60 Curaxin 60 RhuDex ® 60 Nexavar ® 60 PREOS 60 SIRT1 activators 60 Nexavar sorafenib tablets 60 alpha folate receptor 60 Completes Patient Enrollment 60 ZYBRESTAT 60 Fovea Pharmaceuticals subsidiary 60 Phase 2b clinical trials 60 candidates Azedra TM 60 Serdaxin 60 Phase 1a clinical 60 NGX# 60 efaproxiral 60 rhIGFBP 3 60 LPA1 60 pharmacodynamic effects 60 StaphVAX R 60 sulfonylhydrazine class 60 Abiraterone acetate 60 solithromycin 60 squalamine 60 tesetaxel 60 ThermoDox 60 atacicept 60 Lovaxin C 60 XL# XL# XL# XL# 60 tecarfarin 60 anticancer therapeutics 60 Phase III Clinical Trial 60 lesinurad 60 please visit www.advaxis.com 60 Aptocine 60 myeloproliferative diseases 60 GGF2 60 Phase IIIb clinical 60 alvimopan 60 Genitope Corporation 60 antiproliferative effects 60 dexpramipexole 60 GAMMAGARD 60 AEGR 60 MAbs targeting 60 MyVax ® 60 PROVENGE ® 60 PD LID 60 vaginally administered lidocaine 60 confirmatory pivotal 60 HDL Selective Delipidation 60 Intravenous CP 60 Lymphoseek ® 60 orally dosed 60 R#/MEM 60 Phase IIa trial 60 product TNFerade TM 60 liprotamase 60 CIMZIA ™ 60 isavuconazole 60 selective orally bioavailable 60 JAK2 Inhibitor 60 eTag assays 60 modulator SERM 60 placebo controlled clinical 60 Randomized Phase 60 nitazoxanide 60 SinuNase ™ 60 delafloxacin 60 Protexia R 60 TKM ApoB 60 SILENOR TM 60 TransVax TM 60 ZOLINZA 60 CORLUX CORT # 60 rBChE 60 Aeolus Pharmaceuticals Announces 60 Panzem NCD 60 miRview mets 60 HuCNS SC cells 60 BRIM2 60 gamma secretase inhibitor 60 selective androgen receptor modulators 60 ELND# 60 aerosolized AAT 60 Augment TM 60 Acute Radiation Syndrome ARS 60 CXB# 60 Golimumab 60 atherosclerosis regression 60 Posiphen 60 Asentar 60 TH# [003] 60 telomerase inhibitor drug 60 Aurora Kinase 60 subcutaneous PRO 60 regorafenib 60 neovascular diseases 60 sorafenib Nexavar 60 candidate Puricase 60 multiple ascending dose 60 hepatitis C viral infection 60 octreotide implant 60 proteasome inhibitor 60 lintuzumab SGN 60 CDK cyclin dependent 60 ZFP Therapeutic 60 phase III ACCLAIM 60 Ostabolin C TM 60 SILENOR 60 DermaVir Patch 60 phase IIb III 60 recurrent glioblastoma multiforme 60 STRIDE PD 60 Phase 1b clinical 60 Viramidine 60 Bendavia 60 triphendiol 60 IAP inhibitors 60 Muraglitazar 60 prognostic markers 60 GVAX ® 60 generation radiolabeled antibody 60 registrational Phase 60 essential thrombocythemia ET 60 immunomodulatory properties 60 evaluating bafetinib 60 malignant mesothelioma Alfacell 60 epothilone 60 intravenous belinostat 60 ALN TTR# 60 GATTEX TM 60 visilizumab 60 BIBW 60 vivo preclinical 60 CINOD 60 Ketotransdel 60 recombinant PSMA vaccine 60 molecularly targeted 60 Voreloxin 60 telomerase inhibitor 60 phase Ib 60 Reolysin 60 synthetic retinoid 60 NYSE Amex PTN 60 chronic thromboembolic pulmonary 60 ThermoDox ® 60 E2F Decoy 60 Tarceva TM 60 protein tyrosine phosphatase 1B 60 MAXY VII 60 Fodosine 60 recurrent glioma 60 Amigal TM 60 plasma kallikrein inhibitor 60 biologic therapeutics 60 ACTEMRA TM 60 AZILECT ® 60 Kamada AAT 60 oral talactoferrin 60 romazarit 60 epothilones 60 recurrent NSCLC 60 OMP #R# 60 CCR5 mAb 60 Epothilones 60 Phase #/#a clinical 60 Genasense ® 60 Phase 2b trial 60 protein kinase inhibitor 60 nasal decolonization 60 dasatinib Sprycel ® 60 Diabetic Macular Edema 60 cancer neuroendocrine tumor 60 SAR# [004] 60 EnzymeRx 60 bortezomib Velcade 60 CCX# B 60 Silodosin 60 cetuximab Erbitux 60 Cerashield 60 molecular imaging radiopharmaceuticals 60 nalbuphine ER 60 PROSTASCINT R 60 IIa trials 60 safety tolerability pharmacokinetic 59 Azedra ™ 59 Chemophase 59 AzaSite Plus 59 catalytic antioxidant compounds 59 Civacir 59 HDACi 59 blinatumomab 59 MyVax personalized immunotherapy 59 non nucleoside HCV 59 androgen independent 59 reslizumab 59 OMNARIS HFA 59 oral rivaroxaban 59 LungAlert TM 59 ProLindac 59 Preclinical studies suggest 59 hormone LHRH antagonist 59 HSP# inhibitor 59 II Clinical Trial 59 gefitinib Iressa 59 KRN# 59 custirsen 59 iroxanadine 59 Arginox 59 Elocalcitol 59 Phase 2b Clinical Trial 59 lumiliximab 59 nilotinib Tasigna ® 59 class mGluR5 inhibitor 59 NeuVax 59 GEM OS2 59 non porcine pancreatic 59 Restanza 59 Naproxcinod 59 Surfaxin LS 59 CRD5 59 preclinical 59 Tamibarotene 59 siRNA therapeutics 59 bexarotene 59 RiVax 59 Thiarabine 59 JAK3 59 Aurora kinase inhibitor 59 GRNVAC1 59 Exherin 59 lintuzumab 59 LibiGel ® testosterone gel 59 ZACTIMA 59 imatinib Gleevec ® 59 XL# XL# XL# 59 overactive bladder VANTAS R 59 secretory phospholipase A2 sPLA2 59 Dasatinib 59 HCD# [002] 59 Tarvacin Anti Viral 59 EP #R 59 XL# [003] 59 external counterpulsation systems 59 DGAT1 inhibitors